Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 13/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | PPIA | P62937 | 2/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163849 | 0.96 | PPIA (0.64) | P2RY1EPHX2PPIAP2RY14P2RY2 | |
| SCHEMBL3157901 | 0.94 | P2RY1 (0.57) | P2RY1EPHX2PPIAP2RY14P2RY2 | |
| SCHEMBL3147715 | 0.93 | P2RY1 (0.63) | P2RY1EPHX2PPIAP2RY14P2RY2 | |
| SCHEMBL5176105 | 0.85 | P2RY1 (0.59) | P2RY1EPHX2PPIAP2RY14P2RY2 | |
| SCHEMBL12952782 | 0.83 | BRD4 (0.52) | P2RY1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2875663 | 0.81 | P2RY1 (0.54) | P2RY1EPHX2STING1FPR2IGF1R | |
| SCHEMBL21810510 | 0.81 | PPIA (0.76) | PPIANPC1MAPTSMN1; SMN2 | |
| SCHEMBL7760029 | 0.81 | NPC1 (0.67) | PPIANPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3158339 | 0.79 | P2RY1 (0.86) | P2RY1P2RY14P2RY2 | |
| SCHEMBL2877802 | 0.79 | P2RY1 (0.54) | P2RY1EPHX2STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751113-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-10 | — | — | EP | claimed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | claimed |
| EP-1751113-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Pharma Company (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005113511-A9 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2005113511-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | claimed |
| EP-4094762-A1 | TREATMENT OF NEUROLOGICAL INDICATIONS | UCL Business Ltd (GB) | 2022-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267119-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | P2RY1 1/4885EPHX2 1710/4885PPIA 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.